GOVX B11

Drug Profile

GOVX B11

Alternative Names: GEO-D03 DNA vaccine; GeoVax Clade B DNA/MVA HIV/AIDS Vaccine; GOVX-B; pGA2-JS7 + MVA/HIV62

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GeoVax Labs; National Institute of Allergy and Infectious Diseases
  • Developer GeoVax Labs
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 09 Nov 2017 GeoVax plans an additional phase I trial for HIV infection in USA
  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections in USA (IM, Injection)
  • 14 Mar 2017 GeoVax enters into collaboration with American Gene Technologies for the development of a functional cure for HIV infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top